Martin Auster
Stock Analyst at UBS
(1.40)
# 2,451
Out of 4,479 analysts
29
Total ratings
51.61%
Success rate
4.72%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $82.22 | +45.95% | 2 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $40.96 | +156.35% | 1 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | n/a | $6.10 | - | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | n/a | $5.96 | - | 2 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | n/a | $0.46 | - | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | n/a | $12.83 | - | 2 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | n/a | $317.05 | - | 3 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | n/a | $5.72 | - | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | n/a | $64.50 | - | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | n/a | $7.63 | - | 1 | Jan 11, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | n/a | $154.20 | - | 2 | Jan 8, 2021 | |
| CVAC CureVac | Downgrades: Underperform | n/a | $3.34 | - | 2 | Dec 10, 2020 | |
| QURE uniQure | Maintains: Outperform | n/a | $4.01 | - | 1 | Nov 20, 2020 | |
| KURA Kura Oncology | Maintains: Outperform | n/a | $20.58 | - | 2 | Oct 8, 2020 | |
| ESPR Esperion Therapeutics | Downgrades: Neutral | n/a | $2.34 | - | 1 | Aug 11, 2020 | |
| RNA Avidity Biosciences | Initiates: Outperform | n/a | $38.80 | - | 1 | Jul 7, 2020 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | n/a | $22.15 | - | 1 | Jun 2, 2020 | |
| ANAB AnaptysBio | Maintains: Neutral | n/a | $23.94 | - | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $82.22
Upside: +45.95%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $40.96
Upside: +156.35%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.10
Upside: -
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: n/a
Current: $5.96
Upside: -
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: n/a
Current: $0.46
Upside: -
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: n/a
Current: $12.83
Upside: -
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: n/a
Current: $317.05
Upside: -
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: n/a
Current: $5.72
Upside: -
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: n/a
Current: $64.50
Upside: -
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.63
Upside: -
Sarepta Therapeutics
Jan 8, 2021
Maintains: Neutral
Price Target: n/a
Current: $154.20
Upside: -
CureVac
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $3.34
Upside: -
uniQure
Nov 20, 2020
Maintains: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Kura Oncology
Oct 8, 2020
Maintains: Outperform
Price Target: n/a
Current: $20.58
Upside: -
Esperion Therapeutics
Aug 11, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.34
Upside: -
Avidity Biosciences
Jul 7, 2020
Initiates: Outperform
Price Target: n/a
Current: $38.80
Upside: -
Intellia Therapeutics
Jun 2, 2020
Maintains: Neutral
Price Target: n/a
Current: $22.15
Upside: -
AnaptysBio
May 7, 2020
Maintains: Neutral
Price Target: n/a
Current: $23.94
Upside: -